Autohome Inc. Announces Extension of Share Repurchase Program Autohome Inc. Announces Extension of Share Repurchase Program

PR Newswire

BEIJING, Aug. 14, 2025

BEIJING, Aug. 14, 2025 /PRNewswire/ -- Autohome Inc. (NYSE: ATHM; HKEX: 2518) ("Autohome" or the "Company"), the leading online destination for automobile consumers in China, today announced that its board of directors (the "Board") has approved an extension of the term of a share repurchase program (the "Share Repurchase Program") through December 31, 2025. The Share Repurchase Program was originally authorized by the Board in September 2024, under which the Company may repurchase up to US$200 million of its American depositary shares ("ADSs") over the twelve months following September 4, 2024, the announcement date of such program. As of August 8, 2025, the Company had repurchased 5,422,647 ADSs for a total cost of approximately US$144 million.

The Company's proposed repurchases through extension of the Share Repurchase Program may be made from time to time through open market transactions at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on the market conditions and in accordance with applicable rules and regulations. The Board will review the authorized extension of the Share Repurchase Program periodically, and may authorize adjustment of its terms and size or suspend or discontinue the program. The Company plans to fund repurchases from its existing cash balance.

About Autohome Inc.

Autohome Inc. (NYSE: ATHM; HKEX: 2518) is the leading online destination for automobile consumers in China. Its mission is to relentlessly reduce auto industry decision-making and transaction costs driven by advanced technology. Autohome provides occupationally generated content, professionally generated content, user-generated content, and AI-generated content, a comprehensive automobile library, and extensive automobile listing information to automobile consumers, covering the entire car purchase and ownership cycle. The ability to reach a large and engaged user base of automobile consumers has made Autohome a preferred platform for automakers and dealers to conduct their advertising campaigns. Further, the Company's dealer subscription and advertising services allow dealers to market their inventory and services through Autohome's platform, extending the reach of their physical showrooms to potentially millions of internet users in China and generating sales leads for them. The Company offers sales leads, data analysis, and marketing services to assist automakers and dealers with improving their efficiency and facilitating transactions. Autohome operates its "Autohome Mall," a full-service online transaction platform, to facilitate transactions for automakers and dealers. Further, through its websites and mobile applications, it also provides other value-added services, including auto financing, auto insurance, used car transactions, and aftermarket services. For further information, please visit https://www.autohome.com.cn.

Safe Harbor Statement 

This press release contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "anticipates", "future", "intends", "plans", "believes", "estimates" and similar statements. Statements that are not historical facts, including statements about Autohome's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. Further information regarding these and other risks is included in Autohome's filings with the SEC and announcements on the website of the Hong Kong Stock Exchange. All information provided in this press release is as of the date of this press release, and Autohome does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

Autohome Inc.Sterling SongInvestor Relations Director  Tel: +86-10-5985-7483E-mail: ir@autohome.com.cn

Christensen China Limited Suri ChengTel: +86-185-0060-8364E-mail:  suri.cheng@christensencomms.com

View original content:https://www.prnewswire.com/news-releases/autohome-inc-announces-extension-of-share-repurchase-program-302529960.html

SOURCE Autohome Inc.

View less «

What dreams are made of - Exclusive interview with dream weaver Wang Chaoge What dreams are made of - Exclusive interview with dream weaver Wang Chaoge

PR Newswire

BEIJING, Aug. 14, 2025

BEIJING, Aug. 14, 2025 /PRNewswire/ -- A report from chinadaily.com.cn: 

 

You've heard the phrase: "getting lost in a good book". Well, thanks to ingenious architecture, bold artistic devices and carefully-designed theaters, Unique Dream of Red Mansion artistic complex in Langfang, Hebei province, enables fans of the eponymous Chinese classic to do literally just that .

The novel written by Cao Xueqin, A Dream of Red Mansions, is an epic work that holds a mirror up to Chinese society during the Qing Dynasty (1644-1911), set against the backdrop of the rise and fall in the fortunes of four influential families.

Inspired by the novel's philosophy, Wang Chaoge, as general planner, director, and playwright, built Unique Dream of Red Mansion artistic complex to be a fusion of literature, architecture, technology and memory. She believes there are no words to describe what she has created, adding that even "dreamland" doesn't cover its scope.

The ambitious project officially opened on July 23, 2023, and is now celebrating its second anniversary.

"I wanted to bewilder visitors, and to keep everyone guessing what this place really is. I want to make you feel as if you've never seen anything like it," Wang explains.

"I aimed to shatter your preconceptions. For here, a new genre is born, one that, unless you witness it, defies all imagination; a place beyond mental sketching. Before its conception, no-one ever merged theaters into a drama settlement cluster on such a scale."

The Unique Dream of Red Mansion is a labyrinth of 108 spaces and 21 immersive performances, where audiences drift between reality and illusion, past and present.

According to the latest figures, the complex has been in continuous operation for 730 days, attracting over two million visitors and staging more than 21,000 immersive performances. During this year's summer vacation, visitor traffic saw an increase of about 60 percent.

The scenes and elements are inspired by the novel, with each location given a poetic name from the book, touching the audience's senses through the shifting currents of an epic that has haunted Chinese hearts for centuries.

Wang spent nearly eight years bringing this project to life. As a keen lover of the novel, Wang believes it's not merely a book to be staged, but an infinite canvas.

"Everyone has their own dream of Red Mansions," Wang adds, "It is the dream you read, but never finish."

The performances within the complex unfold along two intertwined threads: one re-imagines the most iconic and climactic moments from the novel itself; the other explores the stories that have emerged throughout the years between readers and the novel.

"And, I especially hope that, after you leave, a part of you will linger here, immersed for a long time. Because throughout the whole place, what we provide is experience," Wang adds.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/what-dreams-are-made-of---exclusive-interview-with-dream-weaver-wang-chaoge-302530014.html

SOURCE chinadaily.com.cn

View less «

Commitbiz Dubai Office Awarded ISO Certifications Commitbiz Dubai Office Awarded ISO Certifications

PR Newswire

DUBAI, UAE, Aug. 14, 2025

DUBAI, UAE, Aug. 14, 2025 /PRNewswire/ -- Commitbiz LLC, a leading corporate service provider (CSP) having their head office in Dubai, UAE has been recently awarded prestigious ISO certifications. The recognition comes from authorities like SCK Certifications Pvt. Ltd. and QCAS Certifications Inc.

The firm which helps with business incorporation has been granted the ISO 9001 certification for Quality Management Systems and the ISO 20700 certification for its unwavering commitment to improve the effectiveness and transparency of consultancy engagements between clients and consultants. These certifications were granted after a rigorous evaluation of the company's systems and processes, ensuring they align with internationally recognized standards.

With this accreditation, Commitbiz LLC joins a global league of organizations committed to maintaining stringent quality standards and fostering a culture of accountability.

The ISO certifications reinforce the firm's vision to be a trusted partner in enabling businesses to grow and thrive in the UAE and the Middle East. It also reflects the CSP's dedication to maintaining the highest levels of service delivery across its business setup, consulting, compliance, and support operations.

Speaking on the development, Manu Thomas V, the Managing Director of Commitbiz, stated, "Earning the ISO Certification is not just a milestone, it's a reflection of our team's unwavering commitment to excellence, consistency, and client trust. This achievement reinforces our dedication to delivering quality in everything we do." He reiterated that the firm will continue to provide robust, compliant, and efficient business support services.

About Commitbiz LLC:

Commitbiz, an award-winning Corporate Service Provider (CSP) specialises in offering services related to company formation, corporate tax and accounting, AML compliance, PRO services, regulatory compliance, among others. Established in 2007, it has been at the forefront of business setup in Dubai.

With a client-first approach, the firm empowers entrepreneurs with streamlined, end-to-end solutions tailored to the dynamic Middle Eastern market. To simplify business registration across UAE and other Middle eastern countries they work closely with multiple government authorities.

Since its inception, Commitbiz has accomplished many milestones. These include opening its first branch office in Abu Dhabi, expanding operations to Bahrain, and catering to 10,000+ happy clients across 150+ countries, among others. They have also been bestowed with numerous prestigious awards during the 18-year long journey.

As a trusted name in the field of business incorporation, Commitbiz LLC can help realise entrepreneurial dreams.

Media ContactAvinash Kr. Raiavinash.kr@businesssetup.com

 

View original content:https://www.prnewswire.com/news-releases/commitbiz-dubai-office-awarded-iso-certifications-302530012.html

SOURCE Commitbiz LLC

View less «

Resolutions from the Extraordinary General Meeting in Sinch AB (publ) Resolutions from the Extraordinary General Meeting in Sinch AB (publ)

PR Newswire

STOCKHOLM, Aug. 14, 2025

STOCKHOLM, Aug. 14, 2025 /PRNewswire/ -- Sinch held an extraordinary general meeting on Thursday, 14 August 2025 in Stockholm.

The meeting resolved, in accordance with the board of directors' proposal, to implement a long term incentive program for up to 625 current and future senior executives, key personnel and other employees within the Sinch group ("LTI 2025"). LTI 2025 consists of up to 12,800,000 employee stock options divided into two series: Series 1 for employees outside of Sweden and Series 2 for employees in Sweden. The employee stock options are allotted to the participants free of charge and each employee stock option entitles the holder to acquire one share in Sinch at a price corresponding to the market value of the Sinch share at grant date of the option. The employee stock options are subject to both performance and time-based vesting conditions.

The board of directors' proposal on authorization for the board of directors to resolve on the acquisition of own shares and transfers of acquired own shares to participants in LTI 2025 did not achieve the required majority at the meeting and was therefore not adopted. The meeting instead resolved, in accordance with the board of directors' secondary proposal, that the financial exposure relating to LTI 2025 may be hedged by Sinch entering into a share swap agreement with a third party on market terms, whereby the third party may in its own name acquire and transfer shares in Sinch to employees who participate in LTI 2025.

For further information, please contactOla ElmelandInvestor Relations DirectorMobile: +46 721 43 34 59E-mail: investors@sinch.com

About Sinch

Sinch is pioneering the way the world communicates. More than 175,000 businesses – including many of the world's largest tech companies – rely on Sinch's Customer Communications Cloud to improve customer experience through mobile messaging, voice and email. Sinch has been profitable and fast-growing since it was founded in 2008. It is headquartered in Stockholm, Sweden, with shares traded at NASDAQ Stockholm: XSTO:SINCH. Learn more at sinch.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/sinch-ab/r/resolutions-from-the-extraordinary-general-meeting-in-sinch-ab--publ-,c4218022

The following files are available for download:

https://mb.cision.com/Main/22250/4218022/3609554.pdf

20250814_Bulletin EGM 2025 ENG

 

View original content:https://www.prnewswire.com/news-releases/resolutions-from-the-extraordinary-general-meeting-in-sinch-ab-publ-302530011.html

SOURCE Sinch AB

View less «

Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma

PR Newswire

NANJING, China, Aug. 14, 2025

NANJING, China, Aug. 14, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the successful completion of patient enrollment in the ongoing single-arm, pivotal registrational clinical trial (CTR20213023) for Opamtistomig (LBL-024), a novel PD-L1/4-1BB bispecific antibody.

This marks the world's first registrational clinical trial evaluating an immunotherapy monotherapy for extrapulmonary neuroendocrine carcinoma (EP-NEC). The study, led by Professor Shen Lin from Peking University Cancer Hospital and conducted across multiple medical centers, aims to evaluate the efficacy and safety of Opamtistomig in patients with advanced EP-NEC who failed at least two lines of chemotherapy.

EP-NEC is a highly aggressive, immunologically "cold" tumor. The current first-line standard treatment for advanced EP-NEC remains platinum-based chemotherapy, with an objective response rate (ORR) of 30%-50% and a median overall survival (mOS) of approximately 1 year. For patients with platinum-resistant, no established second-line standard of care exists, representing a pressing unmet need for new therapeutic options.

Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated:" As the first PD-L1/4-1BB-targeted bispecific antibody globally to have reached pivotal single-arm registrational stage, Opamtistomig has demonstrated compelling antitumor activity and favorable safety in early trials. Completing enrollment months ahead of schedule accelerates clinical development timelines and reflects both strong confidence of investigators in the trial design and the urgent patient need for effective, safer therapies. We remain committed to advancing rigorous clinical development across multiple indications, including EP-NEC."

Dr. Xiaoqiang Kang, Founder, Chairman and CEO of Leads Biolabs, added, "This achievement was made possible by the exceptional execution of our clinical team, the dedication of investigators, and the trust of patients and their families. Every data point in this study represents hope for patients facing a devastating disease. Guided by our mission-care for life, focus on innovation, and win win cooperation-we will continue to invest in R&D to accelerate Opamtistomig's global development and deliver transformative therapies worldwide."

About Opamtistomig

Opamtistomig (LBL-024) is a potential first-in-class bispecific antibody simultaneously targeting PD-L1 and the co-stimulatory receptor 4-1BB. It is the first 4-1BB-targeting bispecific antibody globally to reach the single arm pivotal trial stage as a monotherapy and holds promise to become the first approved treatment specifically for extrapulmonary neuroendocrine carcinoma (EP-NEC), a malignancy with significant unmet medical need.

Developed using Leads Biolabs' proprietary X-Body™ bispecific platform, Opamtistomig features a 2:2 format with two binding domains each for PD-L1 and 4-1BB, and an optimized affinity ratio. This design allows Opamtistomig to both reverse PD-L1–mediated immune suppression and selectively enhance T cell activation, resulting in potent, synergistic anti-tumor effects.

In Phase I/II clinical trials in China, Opamtistomig has demonstrated promising efficacy and a favorable safety profile in patients with advanced EP-NEC, both as monotherapy and in combination with chemotherapy. The lack of a standard of care in EP-NEC supports the pursuit of accelerated approval through a single-arm pivotal study.

In recognition of its clinical potential, Opamtistomig received Breakthrough Therapy Designation (BTD) from the National Medical Products Administration (NMPA) in China (October 2024), and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for neuroendocrine carcinoma (November 2024).

Notably, 4-1BB agonism can reactivate exhausted T cells and drive robust proliferation, making it particularly promising for PD-1/PD-L1-resistant or immunologically "cold" tumors. Beyond EP-NEC, Opamtistomig has been approved for clinical trial across multiple cancer types with high unmet need, including small cell lung cancer (SCLC), biliary tract cancer (BTC), ovarian cancer (OC), non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC), triple-negative breast cancer (TNBC), and malignant melanoma. Encouraging clinical activity has already been observed in SCLC, BTC, OC, and other cancer types, supporting Opamtistomig's potential as a broad-spectrum oncology therapy.

About EP-NEC

Neuroendocrine carcinoma (NEC) is a class of poorly differentiated, high-grade neuroendocrine neoplasms (NENs), which originate in the diffuse neuroendocrine cell system and can occur in many different sites. NEC can be categorized into pulmonary NEC and EP-NEC. EP-NEC exhibits similar highly aggressive and metastatic characteristics to small cell lung cancer (SCLC). Most patients are diagnosed at a later stage or already have distant metastases, resulting in rapid disease progression and a poor prognosis.

Currently, the primary first-line treatment for advanced EP-NEC involves platinum-based chemotherapy, achieving an overall response rate (ORR) of approximately 30% to 50%, with a median overall survival (mOS) of only approximately one year. Treatment options for patients with platinum-resistant are limited, and there are no established second-line standard of care for patients who progress after first-line therapy. These underscore the urgency to develop novel therapeutic approaches.

About Leads Biolabs

Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology, autoimmune, and other severe diseases both in China and globally.

We are a front-runner in next-generation immuno-oncology treatments with a differentiated pipeline of 14 innovative drug candidates, including six clinical-stage drug candidates, of which four lead products are among the top-tier clinically advanced candidates globally.

We adopt a science-driven R&D approach and have successfully established comprehensive R&D capabilities spanning antibody discovery and engineering, in vivo and in vitro efficacy evaluation, as well as druggability assessment. We have also developed multiple proprietary technology platforms, including LeadsBody™ platform (a CD3 T-cell engager platform), X-body™ platform (a 4-1BB engager platform), which serve as the cornerstone for our continued innovation and have been validated by the clinical outcomes of our bispecific antibody portfolios.

We have established integrated capabilities across early discovery, translational medicine, clinical development, CMC and business development. The innovative nature and competitive strengths of our drug candidates, coupled with our global perspectives, proactive strategy, and efficient clinical validation, have made us an attractive partner for leading industry players and venture capitals. For more information, please visit https://en.leadsbiolabs.com/

View original content:https://www.prnewswire.com/news-releases/leads-biolabs-announces-completion-of-patient-enrollment-in-pivotal-trial-of-opamtistomig-monotherapy-for-extrapulmonary-neuroendocrine-carcinoma-302530006.html

SOURCE Leads Biolabs

View less «

Max Stock Limited announces an AGM to be held on September 18, 2025 Max Stock Limited announces an AGM to be held on September 18, 2025

PR Newswire

CAESAREA, Israel, Aug. 14, 2025

CAESAREA, Israel, Aug. 14, 2025 /PRNewswire/ -- Max Stock Ltd. (TASE: MAXO) (the "Company") announces an AGM to be held at 10:00AM on September 18, 2025 (date of record: August 28, 2025), at the offices of the Company's external legal counsel Herzog Fox Neeman & Co., 6 Itzhak Sadeh St., Tel Aviv, with the following agenda items:

Discussion on both the Company's 2024 board report and financial statementsPlease note that this agenda item is only informational and will not be voted upon.Reappointment of the auditor and authorizing the Company's board to establish the auditor's feesProposed resolution: To approve the reappointment of Ernst & Young Israel - Kost Forer Gabbay & Kasierer, to serve as the Company's auditor until the end of the Company's next annual general meeting and to authorize the Company's board of directors to establish its fees.Reappointment of directors (non-external directors) for an additional term of officeProposed resolution: To approve the reappointment of the directors listed below (who are not external directors) currently serving on the Company's board of directors: Ms. Zehavit Cohen, Mr. Ori Max, Mr. Erez Nahum, Ms. Limor Brik-Shay, Mr. Guy Gissin and Ms. Suzan Mazzawi (independent director) for an additional term of service, commencing from the time of them being approved by the general meeting until the Company's next annual general meeting.It should be noted that the appointment of each director will be voted upon separately.Extending the management and consulting services agreement with Moose Holdco Ltd.Proposed resolution: To approve extending the Company's engagement in the management and consulting services agreement pursuant to which Moose Holdco, one of the Company's controlling shareholders, provides the Company with management and consulting services, for an additional 3-year term commencing on September 14, 2025, based on terms and conditions identical to those in the existing agreement between the Company and Moose Holdco Ltd. which is effective until September 14, 2025.Approval of the amended remuneration policyProposed resolution: To approve the Amended Remuneration Policy, whereby it shall be effective for three years from September 14, 2025.Extending the letters of indemnity given to Company officers related to the controlling shareholdersProposed resolution: To approve an extension of the letters of indemnity given by the Company to both current and future Company officers with an affinity with the controlling shareholders, officers related to the controlling shareholders and officers with whom the controlling shareholders may have a personal interest in being granted letters of indemnity, for an additional three-year period commencing on September 14, 2025.Extending the letters of release given to Company officers related to the controlling shareholdersProposed resolution: To approve an extension of the letters of release given by the Company to both current and future Company directors with an affinity with the controlling shareholders, directors related to the controlling shareholders and directors with whom the controlling shareholders may have a personal interest in being granted letters of release, for an additional three-year period commencing on September 14, 2025.

A convenience translation into English of the general meeting notice and the relevant voting card can be accessed at https://ir.maxstock.co.il/en/shareholders-meetings/

About Max StockMax Stock is Israel's leading extreme value retailer, currently present in 64 locations throughout Israel. We offer a broad assortment of quality products for customers' everyday needs at affordable prices, helping customers "Dream Big, Pay Small". For more information, please visit https://ir.maxstock.co.il

Company Contacts:Talia Sessler,Chief Corporate Development and IR Officertalia@maxstock.co.il

View original content:https://www.prnewswire.com/news-releases/max-stock-limited-announces-an-agm-to-be-held-on-september-18-2025-302530008.html

SOURCE Max Stock Limited

View less «

CCTV+: Foreign Journalists Open Blind Boxes at Shuiting Gate CCTV+: Foreign Journalists Open Blind Boxes at Shuiting Gate

PR Newswire

BEIJING, Aug. 14, 2025

BEIJING, Aug. 14, 2025 /PRNewswire/ -- Foreign Journalists Open Blind Boxes at Shuiting Gate: Each Brought Surprises.

Video - https://mma.prnewswire.com/media/2750526/Foreign_Journalists_Open_Blind_Boxes_at_Shuiting_Gate.mp4

View original content:https://www.prnewswire.co.uk/news-releases/cctv-foreign-journalists-open-blind-boxes-at-shuiting-gate-302530002.html

View less «

Amcor reports fiscal 2025 Q4 results. Expects strong earnings growth in fiscal 2026. Amcor reports fiscal 2025 Q4 results. Expects strong earnings growth in fiscal 2026.

PR Newswire

ZURICH, Aug. 14, 2025

Fourth Quarter ending June 30, 2025 highlights:

All-stock acquisition of Berry Global Group, Inc. ("Berry Global") closed on April 30, 2025;Identified Amcor's core portfolio and optimization actions;Net sales $5,082 million, up 43% excluding currency impact;GAAP Net Income ($39) million including acquisition related costs; andAdjusted EBITDA $789 million up 43% and adjusted EBIT $611 million up 34% excluding currency impact.

Fiscal Year ending June 30, 2025 highlights:

Net sales $15,009 million, up 11% excluding currency impact;GAAP Net Income $511 million and GAAP diluted EPS 32.0 cps including acquisition related costs;Adjusted EBITDA $2,186 million, up 13%, and adjusted EBIT $1,723 million, up 12% excluding currency impact;Adjusted EPS 71.2 cps, up 3% excluding currency impact; andAdjusted Free Cash Flow $926 million, and annual dividend increased to 51 US cents per share.

Fiscal 2026 outlook: 

Adjusted EPS of 80-83 cps representing 12-17% constant currency growth; Free Cash Flow of $1.8-1.9 billion. 

ZURICH, Aug. 14, 2025 /PRNewswire/ --

Milestone quarter leaves Amcor positioned to deliver strong earnings and free cash flow growth in FY26

Amcor CEO Peter Konieczny said, "This quarter marks a significant milestone for Amcor.  The acquisition of Berry Global transforms our ability to create significant value for our customers and shareholders.  This is clearly reflected in our expectation to deliver strong adjusted EPS growth of 12-17% and a significant increase in Free Cash Flow to  $1.8 to $1.9 billion in fiscal 2026. 

Feedback from our customers has been positive and has already resulted in business wins directly linked to this combination. Integration efforts began on Day 1 and I am proud of the excellent progress our teams have made.  We are tracking well against our synergy targets and our delivery run rate is building as expected.  In addition, through our strategic portfolio review, we have identified Amcor's $20 billion core portfolio of consumer packaging and dispensing solutions for nutrition and health along with optimization actions designed to further sharpen our focus on attractive categories and drive faster growth. 

Our efforts share one common objective: to create an even stronger business, that is the global packaging partner of choice for our customers, and delivers higher levels of consistent organic growth and value for our shareholders."

Key Financials(1)(2)(3)

Three Months Ended June 30,

Twelve Months Ended June 30,

GAAP results

2024 $ million

2025 $ million

2024 $ million

2025 $ million

Net sales

3,535

5,082

13,640

15,009

Net income

257

(39)

730

511

EPS (diluted US cents)

17.8

(1.9)

50.5

32.0

Three Months Ended June 30,

Constant

currency ?%

Twelve Months Ended June 30,

Constant

currency ?%

Adjusted non-GAAP results

2024 $ million

2025 $ million

2024 $ million

2025 $ million

Net sales

3,535

5,082

43

13,640

15,009

11

EBITDA

550

789

43

1,962

2,186

13

EBIT

454

611

34

1,560

1,723

12

Net income

305

408

34

1,015

1,136

13

EPS (diluted US cents)(4)

21.1

20.0

(5)

70.2

71.2

3

Free Cash Flow

837

943

952

926

 

All amounts referenced throughout this document are in US dollars unless otherwise indicated and numbers may not add up to the totals provided due to rounding.  Further details related to combined volume commentary throughout this document can be found under "Presentation of combined volume performance."(1)  Adjusted non-GAAP results exclude items not considered representative of ongoing operations. Constant currency ?% excludes movements in foreign exchange rates.  Further details on non-GAAP measures and reconciliations to GAAP measures can be found under "Presentation of non-GAAP information" in this release.

(2) Due to closing of the combination between Amcor and Berry Global on April 30, 2025, unless otherwise specified, all results within this document for the three months ended 30 June 2025 do not include the results for the legacy Berry Global business for the month of April 2025.  Results for the twelve months ended 30 June 2025 do not include results for the legacy Berry Global business for the months of July 2024 to April 2025.

(3)  Unless otherwise specified, all results within this document for the three months ended 30 June 2024 and the twelve months ended June 30, 2024 reflect the historical results of the Amcor plc group which is considered the accounting acquirer in the combination between Amcor plc and Berry Global, which closed on April 30, 2025.

(4) For fiscal 2025, the sum of quarters do not equal the total year amount due to the impact of changes in average quarterly shares outstanding.

Berry Global acquisition

On April 30, 2025, the all-stock acquisition of Berry Global was completed at a fixed exchange ratio of 7.25 Amcor ordinary shares for each Berry share.

This transformational acquisition establishes Amcor as the global leader in consumer packaging and dispensing solutions for nutrition and health, with the unique material science and innovation capabilities to meet customers' and consumers' sustainability aspirations. With multiple new growth opportunities and $650 million of identified synergies through fiscal 2028, Amcor is well placed to deliver significant near- and long-term value for customers and shareholders. 

Segment reporting

The Global Flexible Packaging Solutions segment includes Amcor's legacy Flexible Packaging business and the newly acquired Berry Global Flexibles business.

The Global Rigid Packaging Solutions segment includes Amcor's legacy Rigid Packaging business and the newly acquired Berry Global Consumer Packaging International and Consumer Packaging North America businesses.

Integration and synergies

Amcor believes the company is well placed to achieve the previously announced total synergy benefits of $650 million (pre-tax) by the end of the 2028 fiscal year. Integration is proceeding in line with expectations and Amcor's teams are on track to deliver $260 million of synergy benefits (pre-tax) in the 2026 fiscal year which represents 12% accretion as a direct result of the acquisition. Given the April 30, 2025 transaction closing date, synergies delivered in the final two months of fiscal 2025 were not material.

Portfolio review identifying Amcor's core portfolio and strategic optimization actions

As previously communicated, the acquisition of Berry Global created a unique opportunity for the company to review its newly combined portfolio. Through this review, the company has identified its $20 billion core portfolio of consumer packaging and dispensing solutions for nutrition and health. This core portfolio is made up of leading positions in large, resilient, and growing health, beauty and wellness, nutrition and specialty end markets, where Amcor has global supply chain flexibility, an expanded multi-format product offering of innovative, high value solutions and significant room to grow. 

The Company also identified businesses with combined annual sales of approximately $2.5 billion that are less aligned with the core portfolio, including the $1.5 billion North America Beverage business and smaller businesses with combined annual sales of approximately $1 billion. Amcor is exploring alternatives to maximize value for each business, which may include restructuring, partnership and joint venture ownership models, cash sale or a combination thereof.  The company believes these optimization actions will enhance focus on these businesses and ensure the core portfolio, drive higher levels of more consistent organic growth and create significant value for shareholders.  

The Company has initiated actions and while there is no definitive timeline, some progress is expected in fiscal 2026. The Company will remain disciplined and focused on maximizing value through the process. 

Shareholder returns

The Amcor Board of Directors today declared a quarterly cash dividend of 12.75 cents per share (compared with 12.5 cents per share in the same quarter last year). Combined with the last three quarterly dividends, this increases the annual dividend for fiscal 2025 to 51.0 cents per share. The dividend will be paid in US dollars to holders of Amcor's ordinary shares trading on the NYSE. Holders of CDIs trading on the ASX will receive an unfranked dividend of 19.59 Australian cents per share, which reflects the quarterly dividend of 12.75 cents per share converted at an AUD:USD average exchange rate of 0.6509 over the five trading days ended August 12, 2025.

The ex-dividend date will be September 4, 2025 for holders of CDIs trading on the ASX and September 5, 2025 for holders of shares trading on the NYSE. For all shareholders, the record date will be September 5, 2025 and the payment date will be September 25, 2025. 

Financial results - Segment information

Three months ended June 30, 2025

Three Months Ended June 30, 2024

Three Months Ended June 30, 2025

Adjusted non-GAAP results

Net sales

$ million

EBIT

$ million

EBIT /

Sales %

Net sales

$ million

EBIT

$ million

EBIT /

Sales %

Global Flexible Packaging Solutions

2,686

403

15.0

3,205

450

14.1

Global Rigid Packaging Solutions

849

75

8.8

1,877

204

10.9

Other(1)

—

(24)

—

(43)

Total Amcor

3,535

454

12.8

5,082

611

12.0

(1) Represents corporate expenses.

Net sales of $5,082 million were 44% higher than last year on a reported basis, including a favorable impact of approximately 1% related to movements in foreign exchange rates.

On a constant currency basis, net sales were 43% higher than last year, including approximately $1.5 billion of acquired sales net of divestments which represents growth of approximately 43%. The remaining year over year variation mainly reflects a favorable impact of approximately 1% related to the pass through of higher raw material costs. Price/mix had a favorable impact of approximately 1% driven by higher relative volume growth in high value categories, which partly offset an unfavorable volume impact of 1.7%. 

Year over year volume performance was similar for both legacy businesses. On a combined basis (includes volume performance for the three months ended June 30, 2025 for the legacy Amcor business combined with volume performance for the period May 1, 2025 to 30 June, 2025 for the legacy Berry business) the Company estimates that volumes were approximately 1.7% lower than the prior year, and approximately 1.4% lower than the prior year excluding North America beverage. 

Adjusted EBIT of $611 million was 34% higher than last year on a constant currency basis, including approximately $200 million of acquired EBIT net of divestments which represents growth of approximately 44%. The remaining year over year variation mainly reflects lower volumes, higher costs in North America beverage business and increased corporate expenses in line with expectations. 

Twelve months ended June 30, 2025   

Twelve Months Ended June 30, 2024

Twelve Months Ended June 30, 2025

Adjusted non-GAAP results

Net sales

$ million

EBIT

$ million

EBIT /

Sales %

EBIT / Average

funds

employed %(1)

Net sales

$ million

EBIT

$ million

EBIT /

Sales %

EBIT / Average

funds

employed %(1)

Global Flexible Packaging Solutions

10,332

1,395

13.5

10,872

1,458

13.4

Global Rigid Packaging Solutions

3,308

259

7.8

4,137

375

9.1

Other(2)

—

(94)

—

(110)

Total Amcor

13,640

1,560

11.4

14.9

15,009

1,723

11.5

12.1

(1) Return on average funds employed includes shareholders' equity and net debt, calculated using a four quarter average and last twelve months

adjusted EBIT.

(2) Represents corporate expenses.

Net sales of $15,009 million were 10% higher than last year on a reported basis, including an unfavorable impact of approximately 1% related to movements in foreign exchange rates.

On a constant currency basis, net sales were 11% higher than last year, including approximately $1.5 billion of acquired sales, net of divestments which represents growth of approximately 10%. The remaining year over year variation mainly reflects a favorable impact of approximately 1% related to the pass through of higher raw material costs. Volumes were up approximately 1% compared with the prior year and price/mix had an unfavorable impact of approximately 1% primarily due to lower volumes in high value healthcare categories in the first half of the year.

Adjusted EBIT of $1,723 million was 12% higher than last year on a constant currency basis including approximately $195 million of acquired EBIT net of divestments, which represents growth of approximately 13%. The remaining year over year variation mainly reflects an unfavorable price/mix impact on earnings, partly offset by benefits from strong cost performance and higher volumes.

Global Flexible Packaging Solutions segment

June 2025 quarter

Three Months Ended June 30,

Reported

?%

Constant

currency ?%

2024 $ million

2025 $ million

Net sales

2,686

3,205

19

18

Adjusted EBIT

403

450

12

11

Adjusted EBIT / Sales %

15.0

14.1

Net sales of $3,205 million were 19% higher than last year on a reported basis, including a favorable impact of approximately 1% related to movements in foreign exchange rates.

On a constant currency basis, net sales were 18% higher than last year, reflecting approximately $420 million of  acquired sales net of divestments which represents growth of approximately 16%. The remaining year over year variation mainly reflects a favorable impact of approximately 1% related to the pass through of higher raw material costs, a favorable price/mix impact of approximately 2%, reflecting higher relative volume growth in high value categories, and an unfavorable volume impact of approximately 1%. 

On a combined basis (includes volume performance for the three months ended June 30, 2025 for the legacy Amcor business combined with volume performance for the period May 1, 2025 to 30 June, 2025 for the legacy Berry business) the Company estimates that overall volumes for the Global Flexible Packaging Solutions segment were approximately 1.5% lower than the prior year. In North America, volumes were down in the low single digit range.  Volumes were higher across focus categories including healthcare, protein (meat and dairy), and liquids. This was offset by lower volumes in other categories including home & personal care, confectionary and unconverted films. Across the balance of the portfolio, volumes were broadly in line with the prior year. In Europe, volumes were lower with growth in pet care, ready meals, medical and dairy, offset by declines in coffee, snacks and confectionary and beauty and wellness. Volumes grew in the low single digit range across emerging markets. 

Adjusted EBIT of $450 million was 11% higher than last year on a constant currency basis, reflecting approximately $50 million of acquired EBIT, net of divestments which represents growth of approximately 12%. The remaining year over year variation mainly reflects lower volumes and an unfavorable earnings impacts from price/mix, partly offset by favorable cost performance. 

Fiscal 2025

Twelve Months Ended June 30,

Reported

?%

Constant

currency ?%

2024 $ million

2025 $ million

Net sales

10,332

10,872

5

6

Adjusted EBIT

1,395

1,458

5

5

Adjusted EBIT / Sales %

13.5

13.4

Net sales of $10,872 million were 5% higher than last year on a reported basis, including an unfavorable impact of approximately 1% related to movements in foreign exchange rates.

On a constant currency basis, net sales were 6% higher than last year, including approximately $410 million of acquired sales net of divestments which represents growth of approximately 4%. The remaining variation mainly reflects a favorable impact of approximately 1% related to the pass through of higher raw material costs, a favorable volume impact of approximately 2% with growth delivered across all key regions, partly offset by an unfavorable price/mix impact of approximately 1% primarily due to lower volumes in high value healthcare categories in the first half of the year. 

Adjusted EBIT of $1,458 million was 5% higher than last year on a constant currency basis, including approximately $50 million of acquired EBIT net of divestments, which represents growth of approximately 3%. The remaining year over year variation mainly reflects benefits from higher volumes and strong cost performance partly offset by unfavorable earnings impacts from price/mix. 

Global Rigid Packaging Solutions segment

June 2025 quarter

Three Months Ended June 30,

Reported

?%

Constant

currency ?%

2024 $ million

2025 $ million

Net sales

849

1,877

121

121

Adjusted EBIT

75

204

173

173

Adjusted EBIT / Sales %

8.8

10.9

Net sales of $1,877 million were 121% higher than last year on a reported and constant currency basis, including approximately $1.1 billion of acquired sales net of divestments which represents growth of approximately 129%. The remaining variation mainly reflects an unfavorable volume impact of approximately 4% and an unfavorable price/mix impact of approximately 4%. Movements in foreign exchange rates and the pass through of higher raw material costs had no material impact on sales for the quarter.

On a combined basis (includes volume performance for the three months ended June 30, 2025 for the legacy Amcor business combined with volume performance for the period May 1, 2025 to 30 June, 2025 for the legacy Berry business) the Company estimates that overall volumes for the Global Rigid Packaging Solutions segment were approximately 2% lower than the prior year and approximately 1% lower than the prior year excluding North America beverage. In North America, volumes declined at low single digit rates excluding North America beverage. Volumes were higher across healthcare, beauty and wellness and foodservice categories. This was more than offset by volume declines in food and specialty end markets. Across the balance of the portfolio, volumes in Europe were in line with the prior year with growth in food and healthcare end markets offset by lower volumes in beauty and wellness categories. Volumes were modestly higher across emerging markets.

Adjusted EBIT of $204 million was 173% higher than last year on a constant currency basis, including approximately $150 million of acquired EBIT net of divestments which represents growth of approximately 203%. The remaining year over year variation mainly reflects lower volumes and higher costs in the North America Beverage business driven by operating challenges at high volume sites.

Fiscal 2025

Twelve Months Ended June 30,

Reported

?%

Constant

currency ?%

2024 $ million

2025 $ million

Net sales

3,308

4,137

25

26

Adjusted EBIT

259

375

45

47

Adjusted EBIT / Sales %

7.8

9.1

Net sales of $4,137 million were 25% higher than last year on a reported basis, including an unfavorable impact of 1% related to movements in foreign exchange rates. 

On a constant currency basis, net sales were were 26% higher than last year, reflecting approximately $1.0 billion of acquired sales net of divestments which represents growth of approximately 31%.  The remaining variation mainly reflects an unfavorable impact of approximately 1% related to the pass through of lower raw material costs, 2% lower volumes and an unfavorable price/mix impact of approximately 2%.

Adjusted EBIT of $375 million was approximately 47% higher than last year on a constant currency basis, reflecting approximately $150 million of acquired EBIT net of divestments, which represents growth of approximately 57%.  The remaining year over year variation mainly reflects lower volumes and higher costs in the North American beverage business in the second half of the year.  

Net interest and income tax expense

For the year ended June 30, 2025, GAAP net interest expense of $347 million compares with $310 million last year.  Adjusted net interest expense of $332 million was $22 million higher than last year as a result of increased acquisition related net debt.  GAAP income tax expense for the year ended June 20, 2025 was $135 million compared with $163 million last year. Adjusted tax expense was $248 million compared with $225 million last year. Adjusted tax expense for the year ended June 30, 2025 represents an effective tax rate of 17.8%, in line with the prior year.

Adjusted Free Cash Flow and Net Debt

For the year ended June 30, 2025, adjusted free cash inflow of $926 million was in-line with the Company's guidance range and compares with $952 million last year.  Net debt was $13,271 million at June 30, 2025, including acquisition related Berry Global debt of approximately $7.4 billion.

Fiscal 2026 Guidance

For the twelve month period ending June 30, 2026, the Company expects:

Adjusted EPS of approximately 80 to 83 cents per share, which represents constant currency growth of 12% to 17% compared with 71.2 cents per share in fiscal 2025. This includes pre-tax synergy benefits related to the Berry Global acquisition of approximately $260 million.Free Cash Flow of approximately $1.8 billion to $1.9 billion, which is after deducting approximately $220 million of net cash integration and transaction costs related to the Berry Global acquisition.

Other guidance considerations include:

Capital expenditure between $850 to $900 million;Net interest expense of approximately $570 to $600 million; andAn effective tax rate between 19% and 21%.

Amcor's guidance for fiscal 2026 reflects a full 12 months ownership of the Berry Global business and does not take into account the impact of potential portfolio optimization actions which may be completed through the year.

Amcor's guidance contemplates a range of factors which create a degree of uncertainty and complexity when estimating future financial results.  Further information can be found under 'Cautionary Statements Regarding Forward-Looking Statements' in this release.  Reconciliations of the fiscal 2026 projected non-GAAP measures are not included herein because the individual components are not known with certainty as individual financial statements for fiscal 2026 have not been completed.

Conference Call

Amcor is hosting a conference call with investors and analysts to discuss these results on Thursday August 14, 2025 at 8:00am US Eastern Daylight Time / 10:00pm Australian Eastern Standard Time. Investors are invited to listen to a live webcast of the conference call at our website, www.amcor.com, in the "Investors" section.

Those wishing to access the call should use the following toll-free numbers, with the Conference ID : 4169471

USA: 800 715 9871 (toll free); 646 307 1963 (local)Australia: 1800 519 630 (toll free), 02 9133 7103 (local)United Kingdom: 0800 358 0970 (toll free), 020 3433 3846 (local)Singapore: 65 3159 5133 (local)Hong Kong: 852 3002 3410 (local)

From all other countries, the call can be accessed by dialing +1 646 307 1963 (toll).

A replay of the webcast will also be available in the 'Investors" section at www.amcor.com following the call.

About Amcor

Amcor is the global leader in developing and producing responsible consumer packaging and dispensing solutions across a variety of materials for nutrition, health, beauty and wellness categories. Our global product innovation and sustainability expertise enables us to solve packaging challenges around the world every day, producing a range of flexible packaging, rigid packaging, cartons and closures that are more sustainable, functional and appealing for our customers and their consumers. We are guided by our purpose of elevating customers, shaping lives and protecting the future. Supported by a commitment to safety, over 75,000 people generate $23 billion in annualized sales from operations that span over 400 locations in more than 40 countries.        NYSE: AMCR; ASX: AMC 

www.amcor.com  I  LinkedIn  I  YouTube

 

U.S. GAAP Condensed Consolidated Statements of Income (Unaudited)

Three Months Ended June 30,

Twelve Months Ended June 30,

($ million, except per share amounts)

2024

2025

2024

2025

Net sales

3,535

5,082

13,640

15,009

Cost of sales

(2,781)

(4,187)

(10,928)

(12,175)

Gross profit

754

895

2,712

2,834

Selling, general, and administrative expenses

(288)

(408)

(1,093)

(1,205)

Amortization of acquired intangible assets

(41)

(130)

(167)

(246)

Research and development expenses

(26)

(38)

(106)

(120)

Restructuring, transaction and integration expenses, net

(15)

(236)

(97)

(307)

Other income/(expense), net

11

4

(35)

53

Operating income

395

87

1,214

1,009

Interest expense, net

(78)

(125)

(310)

(347)

Other non-operating income/(loss), net

1

(9)

3

(12)

Income/loss before income taxes and equity in income/(loss) of

affiliated companies

318

(47)

907

650

Income tax expense

(56)

6

(163)

(135)

Equity in income/(loss) of affiliated companies, net of tax

(1)

2

(4)

3

Net income/loss

261

(39)

740

518

Net income attributable to non-controlling interests

(4)

—

(10)

(7)

Net income/loss attributable to Amcor plc

257

(39)

730

511

USD:EUR average FX rate

0.9287

0.8825

0.9245

0.9203

Basic earnings per share attributable to Amcor

0.178

(0.019)

0.505

0.321

Diluted earnings per share attributable to Amcor

0.178

(0.019)

0.505

0.320

Weighted average number of shares outstanding – Basic

1,439

2,035

1,439

1,589

Weighted average number of shares outstanding – Diluted

1,443

2,040

1,441

1,593

 

U.S. GAAP Condensed Consolidated Statements of Cash Flows (Unaudited)

Twelve Months Ended June 30,

($ million)

2024

2025

Net income

740

518

Depreciation, amortization, and impairment

595

722

Net gain on disposal of businesses and investments

—

(8)

Changes in operating assets and liabilities, excluding effect of acquisitions, divestitures, and

currency

(120)

(53)

Other non-cash items

106

211

Net cash provided by operating activities

1,321

1,390

Purchase of property, plant, and equipment and other intangible assets

(492)

(580)

Proceeds from sales of property, plant, and equipment and other intangible assets

39

18

Business acquisitions and Investments in affiliated companies, and other

(23)

(1,653)

Proceeds from divestitures

—

113

Net debt proceeds/(repayments)

(43)

1,876

Dividends paid

(722)

(845)

Share buy-back/cancellations

(30)

—

Purchase of treasury shares, proceeds from exercise of options and tax withholdings for share-

based incentive plans

(51)

(107)

Other, including effects of exchange rate on cash and cash equivalents

(100)

27

Net increase/decrease in cash and cash equivalents

(101)

239

Cash and cash equivalents at the beginning of the year

689

588

Cash and cash equivalents at the end of the year

588

827

 

U.S. GAAP Condensed Consolidated Balance Sheets (Unaudited)

($ million)

June 30, 2024

June 30, 2025

Cash and cash equivalents

588

827

Trade receivables, net

1,846

3,426

Inventories, net

2,031

3,471

Property, plant and equipment, net

3,763

8,202

Goodwill and other intangible assets, net

6,736

18,679

Other assets

1,560

2,461

Total assets

16,524

37,066

Trade payables

2,580

3,490

Short-term debt and current portion of long-term debt

96

257

Long-term debt, less current portion

6,603

13,841

Accruals and other liabilities

3,292

7,738

Shareholders' equity

3,953

11,740

Total liabilities and shareholders' equity

16,524

37,066

 

Components of Fiscal 2025 Net Sales growth

Three Months Ended June 30

Twelve Months Ended June 30

($ million)

Global

Flexible

Packaging

Solutions

Global Rigid

Packaging

Solutions

Total

Global

Flexible

Packaging

Solutions

Global Rigid

Packaging

Solutions

Total

Net sales fiscal year 2025

3,205

1,877

5,082

10,872

4,137

15,009

Net sales fiscal year 2024

2,686

849

3,535

10,332

3,308

13,640

Reported Growth %

19

121

44

5

25

10

FX %

1

—

1

(1)

(1)

(1)

Constant Currency Growth %

18

121

43

6

26

11

Raw Material Pass Through %

1

—

1

1

(1)

1

Items affecting comparability %

16

129

43

4

31

10

Organic Growth

1

(8)

(1)

1

(4)

—

Volume %

(1)

(4)

(2)

2

(2)

1

Price/Mix %

2

(4)

1

(1)

(2)

(1)

 

Reconciliation of Non-GAAP Measures

Reconciliation of adjusted Earnings before interest, tax, depreciation and amortization (EBITDA), Earnings before interest

and tax (EBIT), Net income, Earnings per share (EPS) and Free Cash Flow

Three Months Ended June 30, 2024

Three Months Ended June 30, 2025

($ million)

EBITDA

EBIT

Net

Income

EPS

(Diluted

US

cents)(1)

EBITDA

EBIT

Net

Income

EPS

(Diluted

US

cents)(1)

Net income attributable to Amcor

257

257

257

17.8

(39)

(39)

(39)

(1.9)

Net income attributable to non-controlling

interests

4

4

—

—

Tax expense

56

56

(6)

(6)

Interest expense, net

78

78

125

125

Depreciation and amortization

136

309

EBITDA, EBIT, Net income and EPS

531

395

257

17.8

389

80

(39)

(1.9)

Impact of highly inflationary accounting

(2)

(2)

(2)

(0.1)

8

8

8

0.4

Restructuring and other related activities, net(2)

15

15

15

1.0

29

29

29

1.4

Berry Transaction & Integration

—

—

—

—

166

166

176

8.6

Merger related compensation

—

—

—

—

41

41

41

2.0

Inventory step-up amortization(3)

—

—

—

—

133

133

133

6.5

Other

5

5

5

0.3

24

24

24

1.2

Amortization of acquired intangibles(4)

41

41

2.9

130

130

6.4

Tax effect of above items

(11)

(0.8)

(94)

(4.6)

Adjusted EBITDA, EBIT, Net income, and EPS

550

454

305

21.1

789

611

408

20.0

Reconciliation of adjusted growth to constant currency growth

% growth - Adjusted EBITDA, EBIT, Net income and EPS

44

35

34

(5)

% currency impact

(1)

—

—

—

% constant currency growth

43

34

34

(5)

% constant currency made up of:

% items affecting comparability (5)

51

44

40

1

% from all other sources

(8)

(10)

(7)

(6)

Adjusted EBITDA

550

789

Interest paid, net

(99)

(123)

Income tax paid

(90)

(138)

Purchase of property, plant and equipment and

other intangible assets

(134)

(220)

Proceeds from sales of property, plant and

equipment and other intangible assets

27

9

Movement in working capital

610

744

Other

(27)

(118)

Adjusted Free Cash Flow

837

943

(1) Calculation of diluted EPS for the three months ended June 30, 2024 excludes net income attributable to shares to be repurchased under forward

contracts of $1 million.   For fiscal 2025, the sum of quarters do not equal the total year amount due to the impact of changes in average quarterly

shares outstanding.

(2) Fiscal 2025 primarily includes restructuring and other costs related to the integration of the acquired Berry business, and costs attributable to

group wide initiatives to partly offset divested earnings from the Russian business.

(3) Additional amortization incurred on inventories in connection with the Berry acquisition

(4) Amortization of acquired intangible assets from business combinations.

(5) Reflects the impact of acquired, disposed, and ceased operations.

 

Twelve Months Ended June 30, 2024

Twelve Months Ended June 30, 2025

($ million)

EBITDA

EBIT

Net

Income

EPS

(Diluted

US

cents)(1)

EBITDA

EBIT

Net

Income

EPS

(Diluted

US

cents)(1)

Net income attributable to Amcor

730

730

730

50.5

511

511

511

32.0

Net income attributable to non-controlling

interests

10

10

7

7

Tax expense

163

163

135

135

Interest expense, net

310

310

347

347

Depreciation and amortization

569

710

EBITDA, EBIT, Net income and EPS

1,782

1,213

730

50.5

1,710

1,000

511

32.0

Impact of highly inflationary accounting

53

53

53

3.7

16

16

16

1.0

Restructuring and other related activities, net(2)

97

97

97

6.7

64

64

64

4.0

Berry Transaction & Integration

—

—

—

—

202

202

217

13.6

Merger related compensation

—

—

—

—

41

41

41

2.6

CEO Transition costs

8

8

8

0.6

—

—

—

—

Inventory step-up amortization(3)

—

—

—

133

133

133

8.3

Other

22

22

22

1.5

21

21

21

1.3

Amortization of acquired intangibles(4)

167

167

11.6

246

246

15.4

Tax effect of above items

(62)

(4.4)

(113)

(7.0)

Adjusted EBITDA, EBIT, Net income and EPS

1,962

1,560

1,015

70.2

2,186

1,723

1,136

71.2

Reconciliation of adjusted growth to constant currency growth

% growth - Adjusted EBITDA, EBIT, Net income, and EPS

11

11

12

1

% currency impact

1

1

1

1

% constant currency growth

13

12

13

3

% constant currency made up of:

% items affecting comparability (5)

14

13

12

1

% from all other sources

(1)

(1)

2

2

Adjusted EBITDA

1,962

2,186

Interest paid, net

(295)

(290)

Income tax paid

(253)

(286)

Purchase of property, plant and equipment and

other intangible assets

(492)

(580)

Proceeds from sales of property, plant and

equipment and other intangible assets

39

18

Movement in working capital

(15)

34

Other

6

(156)

Adjusted Free Cash Flow

952

926

(1) Calculation of diluted EPS for the twelve months ended June 30, 2025 excludes net income attributable to shares to be repurchased under forward

contracts of $1 million. Calculation of diluted EPS for the twelve months ended June 30, 2024 excludes net income attributable to shares to be

repurchased under forward contracts of $3 million.  For fiscal 2025, the sum of quarters do not equal the total year amount due to the impact of

changes in average quarterly shares outstanding.

(2) Fiscal 2025 primarily includes restructuring and other costs related to the integration of the acquired Berry business, and costs attributable to

group wide initiatives to partly offset divested earnings from the Russian business.

(3) Additional amortization incurred on inventories in connection with the Berry acquisition

(4) Amortization of acquired intangible assets from business combinations.

(5) Reflects the impact of acquired, disposed, and ceased operations.

 

Reconciliation of adjusted EBIT by reporting segment

Three Months Ended June 30, 2024

Three Months Ended June 30, 2025

($ million)

Global

Flexible

Packaging

Solutions

Global

Rigid

Packaging

Solutions

Other

Total

Global

Flexible

Packaging

Solutions

Global

Rigid

Packaging

Solutions

Other

Total

Net income attributable to

Amcor

257

(39)

Net income attributable to non-

controlling interests

4

—

Tax expense

56

(6)

Interest expense, net

78

125

EBIT

351

73

(29)

395

308

8

(236)

80

Impact of highly inflationary

accounting

—

(2)

—

(2)

5

3

—

8

Restructuring and other related

activities, net(1)

11

4

—

15

29

—

—

29

Berry Transaction & Integration

—

—

—

—

18

10

138

166

Merger related compensation

—

—

—

—

—

—

41

41

Inventory step-up amortization(2)

—

—

—

—

27

106

—

133

Other

—

—

5

5

2

11

11

24

Amortization of acquired

intangibles(3)

41

—

—

41

62

66

2

130

Adjusted EBIT

403

75

(24)

454

450

204

(43)

611

Adjusted EBIT / sales %

15.0 %

8.8 %

12.8 %

14.1 %

10.9 %

12.0 %

Reconciliation of adjusted growth to constant currency growth

% growth - Adjusted EBIT

12

173

—

35

% currency impact

(1)

—

—

—

% constant currency

11

173

—

34

% constant currency made up of:

% items affecting comparability (4)

12

203

—

44

% from all other sources

(1)

(31)

—

(10)

(1) Fiscal 2025 primarily includes restructuring and other costs related to the integration of the acquired Berry business, and costs attributable to

group wide initiatives to partly offset divested earnings from the Russian business. 

(2) Additional amortization incurred on inventories in connection with the Berry acquisition.

(3) Amortization of acquired intangible assets from business combinations.

(4) Reflects the impact of acquired, disposed, and ceased operations.

 

Twelve Months Ended June 30, 2024

Twelve Months Ended June 30, 2025

($ million)

Global

Flexible

Packaging Solutions

Global

Rigid

Packaging Solutions

Other

Total

Global

Flexible

Packaging Solutions

Global

Rigid

Packaging Solutions

Other

Total

Net income attributable to Amcor

730

511

Net income attributable to non-controlling interests

10

7

Tax expense

163

135

Interest expense, net

310

347

EBIT

1,147

185

(119)

1,213

1,162

180

(342)

1,000

Impact of highly inflationary accounting

—

53

—

53

5

11

—

16

Restructuring and other related activities, net(1)

79

18

—

97

63

1

—

64

Berry Transaction & Integration

—

—

—

—

18

11

173

202

Merger related compensation

—

—

—

—

—

—

41

41

CEO transition costs

—

—

8

8

—

—

—

—

Inventory step-up amortization(2)

—

—

—

—

27

106

—

133

Other

5

—

17

22

12

(4)

13

21

Amortization of acquired intangibles(3)

164

3

—

167

172

70

4

246

Adjusted EBIT

1,395

259

(94)

1,560

1,458

375

(110)

1,723

Adjusted EBIT / sales %

13.5 %

7.8 %

11.4 %

13.4 %

9.1 %

11.5 %

Reconciliation of adjusted growth to constant currency growth

% growth - Adjusted EBIT

5

45

—

11

% currency impact

1

3

—

1

% constant currency growth

5

47

—

12

% constant currency made up of:

% items affecting comparability (4)

3

57

13

% from all other sources

2

(10)

(1)

(1) Fiscal 2025 primarily includes restructuring and other costs related to the integration of the acquired Berry business, and costs attributable to

group wide initiatives to partly offset divested earnings from the Russian business.

(2) Additional amortization incurred on inventories in connection with the Berry acquisition.

(3) Amortization of acquired intangible assets from business combinations.

(4) Reflects the impact of acquired, disposed, and ceased operations.

 

Reconciliation of net debt

($ million)

June 30, 2024

June 30, 2025

Cash and cash equivalents

(588)

(827)

Short-term debt

84

116

Current portion of long-term debt

12

141

Long-term debt excluding current portion

6,603

13,841

Net debt

6,111

13,271

Cautionary Statement Regarding Forward-Looking Statements

Unless otherwise indicated, references to "Amcor," the "Company," "we," "our," and "us" in this document refer to Amcor plc and its consolidated subsidiaries. This document contains certain statements that are "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identified with words like "believe," "expect," "target," "project," "may," "could," "would," "approximately," "possible," "will," "should," "intend," "plan," "anticipate," "commit," "estimate," "potential," "ambitions," "outlook," or "continue," the negative of these words, other terms of similar meaning, or the use of future dates. Such statements are based on the current expectations of the management of Amcor and are qualified by the inherent risks and uncertainties surrounding future expectations generally. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. Neither Amcor nor any of its respective directors, executive officers, or advisors, provide any representation, assurance, or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur or if any of them do occur, what impact they will have on the business, results of operations or financial condition of Amcor. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on Amcor's business, including the ability to successfully realize the expected benefits of the merger of Amcor and Berry Global Group, Inc. Risks and uncertainties that could cause actual results to differ from expectations include, but are not limited to: risks arising from the integration of the Amcor and Berry Global Group, Inc., ("Berry Global") businesses as a result of the Merger completed on April 30, 2025 (the "Transaction"); risk of continued substantial and unexpected costs or expenses resulting from the Transaction; risk that the anticipated benefits of the Transaction may not be realized when expected or at all; risk that the Company's significant indebtedness may limit its flexibility and increase its borrowing costs; risk that the Merger related tax liabilities could have a material impact on the Company's financial results; changes in consumer demand patterns and customer requirements in numerous industries; risk of loss of key customers, a reduction in their production requirements, or consolidation among key customers; significant competition in the industries and regions in which we operate; an inability to expand our current business effectively through either organic growth, including product innovation, investments, or acquisitions; challenging global economic conditions; impacts of operating internationally; price fluctuations or shortages in the availability of raw materials, energy and other inputs, which could adversely affect our business; production, supply, and other commercial risks, including counterparty credit risks, which may be exacerbated in times of economic volatility; pandemics, epidemics, or other disease outbreaks; an inability to attract, develop, and retain our skilled workforce and manage key transitions; labor disputes and an inability to renew collective bargaining agreements at acceptable terms; physical impacts of climate change; significant disruption at key manufacturing facilities; cybersecurity risks, which could disrupt our operations or risk of loss of our sensitive business information; failures or disruptions in our information technology systems which could disrupt our operations, compromise customer, employee, supplier, and other data; rising interest rates that increase our borrowing costs on our variable rate indebtedness and could have other negative impacts; foreign exchange rate risk; a significant write-down of goodwill and/or other intangible assets; a failure to maintain an effective system of internal control over financial reporting; an inability of our insurance policies, including our use of a captive insurance company, to provide adequate protection against all of the key operational risks we face; an inability to defend our intellectual property rights or intellectual property infringement claims against us; litigation, including product liability claims or litigation related to Environmental, Social, and Governance ("ESG") matters, or regulatory developments; increasing scrutiny and changing expectations from investors, customers, suppliers, and governments with respect to our ESG practices and commitments resulting in additional costs or exposure to additional risks; changing ESG government regulations including climate-related rules; changing environmental, health, and safety laws; changes in tax laws or changes in our geographic mix of earnings; and changes in trade policy, including tariff and custom regulations or failing to comply with such regulations.  These risks and uncertainties are supplemented by those identified from time to time in our filings with the Securities and Exchange Commission (the "SEC"), including without limitation, those described under Part I, "Item 1A - Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024, and as updated by our quarterly reports on Form 10-Q. You can obtain copies of Amcor's filings with the SEC for free at the SEC's website (www.sec.gov). Forward-looking statements included herein are made only as of the date hereof and Amcor does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent, except as expressly required by law. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.

Presentation of non-GAAP information

Included in this release are measures of financial performance that are not calculated in accordance with U.S. GAAP. These measures include adjusted EBITDA and EBITDA (calculated as earnings before interest and tax and depreciation and amortization), adjusted EBIT and EBIT (calculated as earnings before interest and tax), adjusted net income, adjusted earnings per share, adjusted free cash flow, net debt and synergies from the Merger.  In arriving at these non-GAAP measures, we exclude items that either have a non-recurring impact on the income statement or which, in the judgment of our management, are items that, either as a result of their nature or size, could, were they not singled out, potentially cause investors to extrapolate future performance from an improper base. Note that while amortization of acquired intangible assets is excluded from non-GAAP adjusted financial measures, the revenue of the acquired entities and all other expenses unless otherwise stated, are reflected in our non-GAAP financial performance earnings measures. While not all inclusive, examples of these items include: material restructuring programs, including associated costs such as employee severance, pension and related benefits, impairment of property and equipment and other assets, accelerated depreciation, termination payments for contracts and leases, contractual obligations, and any other qualifying costs related to restructuring plans; material sales and earnings from disposed or ceased operations and any associated profit or loss on sale of businesses or subsidiaries; changes in the fair value of economic hedging instruments on commercial paper and contingent purchase consideration; pension settlements; impairments in goodwill and equity method investments; material acquisition compensation and transaction costs such as due diligence expenses, professional and legal fees, financing-related expenses; and integration costs; material purchase accounting adjustments for inventory; amortization of acquired intangible assets from business combination; gains or losses on significant property and divestitures and significant property and other impairments, net of insurance recovery; certain regulatory and legal matters; impacts from highly inflationary accounting; expenses related to the Company's Chief Executive Officer transition; and impacts related to the Russia-Ukraine conflict.

Amcor also evaluates performance on a comparable constant currency basis, which measures financial results assuming constant foreign currency exchange rates used for translation based on the average rates in effect for the comparable prior year period. In order to compute comparable constant currency results, we multiply or divide, as appropriate, current-year U.S. dollar results by the current year average foreign exchange rates and then multiply or divide, as appropriate, those amounts by the prior-year average foreign exchange rates. We then adjust for other items affecting comparability. While not all inclusive, examples of items affecting comparability include the difference between sales or earnings in the current period and the prior period related to disposed, or ceased operations. Comparable constant currency net sales performance also excludes the impact from passing through movements in raw material costs.  

Management has used and uses these measures internally for planning, forecasting and evaluating the performance of the Company's reporting segments and certain of the measures are used as a component of Amcor's Board of Directors' measurement of Amcor's performance for incentive compensation purposes. Amcor believes that these non-GAAP measures are useful to enable investors to perform comparisons of current and historical performance of the Company. For each of these non-GAAP financial measures, a reconciliation to the most directly comparable U.S. GAAP financial measure has been provided herein. These non-GAAP financial measures should not be construed as an alternative to results determined in accordance with U.S. GAAP. The Company provides guidance on a non-GAAP basis as we are unable to predict with reasonable certainty the ultimate outcome and timing of certain significant forward-looking items without unreasonable effort.  These items include but are not limited to the impact of foreign exchange translation, restructuring program costs, asset impairments, possible gains and losses on the sale of assets, certain tax related events, and difficulty in making accurate forecasts and projections in connection with the legacy Berry Global business given recency of access to all relevant information. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP earnings and cash flow measures for the guidance period.

Presentation of combined volume performance

In order to provide the most meaningful comparison of results of volume performance by region and end market for the Amcor group and for each of its reportable segments, the Company has included commentary to reflect Amcor's estimate of year-over-year volume performance for the three months ended June 30, 2025 for the legacy Amcor business, combined with year-over-year volume performance for the period May 1, 2025 to June 30, 2025 for the legacy Berry Global business. The combined volume performance information has been presented for informational purposes and Amcor believes this information reflects the impact of the combination, taking into account the allocation of volumes across both legacy businesses was managed on a  combined network basis from May 1, 2025.  The combined volume performance Information should be read in conjunction with the separate historical financial statements and accompanying notes contained in each of the Amcor and Berry Global periodic reports, as available.  For avoidance of doubt, the combined volume performance information is not intended to be, and was not, prepared on a basis consistent with pro forma financial information required by Article 11 of Regulation S-X.

Dividends

Amcor has received a waiver from the ASX's settlement operating rules, which will allow the Company to defer processing conversions between its ordinary share and CDI registers from September 4, 2025 to September 5, 2025 inclusive.

View original content:https://www.prnewswire.com/news-releases/amcor-reports-fiscal-2025-q4-results-expects-strong-earnings-growth-in-fiscal-2026-302529997.html

SOURCE Amcor

View less «

Guidehouse Research Estimates Market for Energy Service Companies' Performance Contracting to Reach Nearly $27 Billion by 2034 Guidehouse Research Estimates Market for Energy Service Companies' Performance Contracting to Reach Nearly $27 Billion by 2034

PR Newswire

BOULDER, Colo., Aug. 14, 2025

ESCO performance contracts gain traction as governments and businesses seek long-term energy savings and resilience

BOULDER, Colo., Aug. 14, 2025 /PRNewswire/ -- A new report from Guidehouse Research analyzes major trends in energy service companies (ESCO) performance contracting.

The energy savings performance contracts (ESPCs) offered by ESCOs can increase cost savings, energy efficiency, and infrastructure resilience across numerous customer segments. According to a new report from Guidehouse Research, the ESCO performance contracting market is expected to expand from $15.9 billion in 2025 to $26.7 billion in 2034, representing a CAGR of 6.0%.

ESPCs can directly benefit federal and municipal government buildings, hospitals, and education facilities. Other beneficiaries include private commercial and industrial (C&I) buildings, utilities, and military institutions.

"Both public and private entities are attracted to the cost savings, infrastructure upgrades, and increased energy efficiency and resilience that result from ESPCs," says Wendy Davis, principal research analyst with Guidehouse Research. "Other key drivers of ESPC use are corporate decarbonization goals, enabling legislation, building performance standards, utility-based programs, energy market participation incentives, and companies with excess capital."

Despite noticeable growth, the ESCO performance contracting market faces noteworthy barriers. Continued growth will depend on stakeholders addressing challenges by increasing awareness of the benefits of using ESPCs as a contracting mechanism. Key market barriers include political uncertainty, a shortage of skilled project managers and engineers, the availability of capital for private companies and the long ROI period for ESPCs, low energy prices in some regions, and diminishing opportunities to increase energy efficiency, according to the report.

The report, ESCO Performance Contracting, analyzes major trends across six customer segments: primary and secondary education, state and local government, federal or national government, higher education, healthcare and hospitals, and C&I. The report also covers six technologies utilized in ESPCs that help customers increase energy efficiency, cost savings, and infrastructure value: HVAC, lighting, building controls, water efficiency, onsite supply and renewables, and EV charging. The report provides an overview of the drivers and barriers for the ESCO performance contracting market and offers recommendations for ESPC stakeholders. An executive summary of the report is available for free download on the Guidehouse Research website.

About Guidehouse Research

Guidehouse Research, the dedicated market intelligence arm of Guidehouse, provides research, data, and benchmarking services for today's rapidly changing and highly regulated industries. Our insights are built on in-depth analysis of global clean technology markets. The team's research methodology combines supply-side industry analysis, end-user primary research, and demand assessment, paired with a deep examination of technology trends, to provide a comprehensive view of emerging resilient infrastructure systems. Additional information about Guidehouse Research can be found at guidehouseresearch.com.

About Guidehouse

Guidehouse is a global AI-led professional services firm delivering advisory, technology, and managed services to the commercial and government sectors. With an integrated business technology approach, Guidehouse drives efficiency and resilience in the healthcare, financial services, energy, infrastructure, and national security markets. Built to help clients across industries outwit complexity, the firm brings together approximately 18,000 professionals to achieve lasting impact and shape a meaningful future. guidehouse.com

* The information contained in this press release concerning the report, ESCO Performance Contracting, is a summary and reflects the current expectations of Guidehouse Research based on market data and trend analysis. Market predictions and expectations are inherently uncertain and actual results may differ materially from those contained in this press release or the report. Please refer to the full report for a complete understanding of the assumptions underlying the report's conclusions and the methodologies used to create the report. Neither Guidehouse Research nor Guidehouse undertakes any obligation to update any of the information contained in this press release or the report.

For more information, contact:

Cecile Fradkin for Guidehouse Research+1.646.941.9139cfradkin@scprgroup.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/guidehouse-research-estimates-market-for-energy-service-companies-performance-contracting-to-reach-nearly-27-billion-by-2034-302526678.html

SOURCE Guidehouse Research

View less «

CCTV+: Foreign Journalists Open Blind Boxes at Shuiting Gate CCTV+: Foreign Journalists Open Blind Boxes at Shuiting Gate

PR Newswire

BEIJING, Aug. 14, 2025

BEIJING, Aug. 14, 2025 /PRNewswire/ -- Foreign Journalists Open Blind Boxes at Shuiting Gate: Each Brought Surprises.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cctv-foreign-journalists-open-blind-boxes-at-shuiting-gate-302529981.html

SOURCE CCTV+

View less «